Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trimethoprim. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.85 |
| ▸ | MEN1 | O00255 | 1/20 | 0.85 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.85 |
| ▸ | TSHR | P16473 | 1/20 | 0.85 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.85 |
| ▸ | BLM | P54132 | 1/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.85 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trimethoprim SCHEMBL29507067 | 1.00 | DHFR (0.85) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL9862147 | 0.99 | DHFR (0.83) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL11162399 | 0.93 | DHFR (0.77) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL29462189 | 0.92 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL2637561 | 0.92 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL24506 | 0.92 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL1236697 | 0.91 | DHFR (0.97) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL29002279 | 0.91 | DHFR (0.97) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL547988 | 0.91 | DHFR (0.97) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL5702287 | 0.91 | DHFR (0.97) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057005-A | External antibacterial pharmaceutical composition, and preparation method and application thereof | 山东序列生物科技有限公司 | 2026-05-19 | — | — | CN | claimed |
| WO-2025094112-A1 | BIOCOMPATIBLE THREE-DIMENSIONAL PRINTED ARTIFICIAL MUSCLES | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2025-05-08 | — | — | WO | claimed |
| US-12274830-B2 | Nitric oxide inhalation therapy for infants with bronchiolitis | BEYOND AIR LTD (IL) | 2025-04-15 | — | — | US | claimed |
| WO-2025030169-A2 | ENHANCED FORMULATION OF POLYMYXIN B/ TRIMETHOPRIM AND RIFAMPIN AND METHODS FOR OPHTHALMIC USES | ARCUM VISION INC. (US) | 2025-02-06 | — | — | WO | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240173512-A1 | METHODS FOR POTENTIATING ANTIMICROBIAL AGENTS | STREETERVILLE CAPITAL, LLC | 2024-05-30 | — | — | US | claimed |
| US-11890421-B2 | Methods for potentiating antimicrobial agents | BEYOND AIR LTD (IL) | 2024-02-06 | — | — | US | claimed |
| CN-117384259-A | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2024-01-12 | — | — | CN | claimed |
| CN-112912386-B | Cell penetrating peptides based on influenza virus M2 proteins | 中国医学科学院基础医学研究所 | 2023-10-20 | — | — | CN | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| CN-1826129-A | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS INC (US) | 2006-08-30 | — | — | CN | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| EP-1384479-A1 | Preventing or reducing photosensitivity and/or phototoxicity reactions to antiinfective medications | G.D. SEARLE & CO. (US) | 2004-01-28 | — | — | EP | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| EP-0741570-B1 | PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO ANTIINFECTIVE MEDICATIONS | SEARLE & CO (US) | 2003-05-07 | — | — | EP | claimed |
| US-6172069-B1 | CONTROLLING TIME OF ADMINISTERING | G. D. SEARLE & COMPANY | 2001-01-09 | — | — | US | claimed |
| EP-0741570-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1996-11-13 | — | — | EP | claimed |
| WO-1995020387-A1 | METHOD FOR PREVENTING OR REDUCING PHOTOSENSITIVITY AND/OR PHOTOTOXICITY REACTIONS TO MEDICATIONS | G.D. SEARLE & CO. (US) | 1995-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | DHFR 69/4885MEN1 1014/4885SLC22A1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.